Canton Strategic Holdings, Inc. Common Stock
CNTNStock
$2.34+36.09%52W
Market Cap$184.32M
P/E—
Div yield—
Beta1.49
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-34.24%
Price vs S&P 500 (4W)-27.95%
VGM Score46.08
Market Capitalization$184.32M
Analyst Recommendations
Sep 2025
Oct 2025
Nov 2025
Dec 2025
4.14
4.14
4.14
4.14
Industry Peers — Pharmaceuticals(563)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
CNTNCanton Strategic Holdings, Inc. Common Stock | — | — | C | $2.34 |
| LLYEli Lilly & Co. | D | B | B | $1169.17 |
| JNJJohnson & Johnson | D | C | B | $249.97 |
| ABBVABBVIE INC. | D | C | B | $254.39 |
| MRKMerck & Co., Inc. | C | C | B | $127.63 |
| NVSNovartis AG | C | C | C | $152.73 |
| NVONovo-Nordisk A/S | C | B | C | $51.48 |
| AZNAstraZeneca PLC | C | B | C | $169.29 |
| ABTAbbott Laboratories | C | C | D | $98.83 |
| PFEPfizer Inc. | B | C | C | $25.14 |
| VRTXVertex Pharmaceuticals Inc | D | C | C | $486.03 |
About
Canton Strategic Holdings Inc operates two distinct business segments: a blockchain infrastructure business centered on the Canton Network, where it runs a validator node and facilitates financial market digitization through Canton Coin, and a clinical-stage biotech company developing therapeutics for neurological and respiratory disorders. The biotech division's lead candidate, GV104, is in clinical development for respiratory and nervous system depression in military personnel and first responders, with plans to expand into additional indications. The pipeline includes GV023 for autoimmune diseases and an early-stage multispecific biologic platform.